{"clientID":"2b71d197-0c21-4234-ba98-2689b888f985","signature":"664610f33aa0503128c41216cec8b65f079ea4ee9ece982d6c7d6715d0fc4e88","encryption":"68cad83b4246825bd81d4bc1059d4620","keyID":"183b753b-7f28-af43-f453-4bd93774f44a","user":"C1AAFC8C323DFDA567B3CD7D0E48C3DD"}


ATLANTE PRIVATE EQUITY ACQUIRES INTEREST IN SVAS BIOSANA

• The investment, made by Atlante Private Equity through share capital increase, is equal to 6 million euro

• The interest in Svas Biosana aims at nationally and internationally supporting the company growth both on a structural level and through possible further acquisitions


Milan, 24 April 2012 – An agreement has been reached over the last few days for the acquisition by Atlante Private Equity - a Private Equity Fund managed by IMI Fondi Chiusi SGR, an Intesa San Paolo Group company - of an interest in Svas Biosana, a company based in Somma Vesuviana (Naples) that has been operating for over 40 years in the sector of medical devices and infusion solutions.

The transaction sees an overall investment of 6 million euro, made through a share capital increase resulting in the acquisition of a company minority share.

Atlante Private Equity aims at supporting and backing a growth path that is already well underway. It wants to extend the company’s reach on a national and international geographical basis by strengthening the current corporate structure as well as through further possible acquisitions currently under consideration.  

“We are delighted to welcome the Atlante Private Equity Fund as one of our shareholders” commented Umberto Perillo, managing director of the Svas Biosana Group. “In such an unsettled economic environment, tackling the challenges posed by the market with the daily support of a financial investor stimulates our growth and consolidation in a sector where competition is becoming ever fiercer”.

“The decision to support the growth of the Svas Biosana Group is based on the Management Team’s skills and great motivations. These factors represent the best conditions for implementing the growth path that the Group has drawn up” stated Antonio Finocchi Ghersi, one of Atlante Private Equity Fund’s senior partners. “The Svas Biosana Group has, over time, demonstrated the ability to readily adopt strategies designed to tangibly meet market needs. Further potential elements to be exploited make us confident that targets set will be achieved” added Antonio Riccio, the Fund’s Investment Director.

 Atlante Private Equity were advised by PWC Transaction Services, with Roberto Leccese of Law Firm Studio Ughi e Nunziante acting as legal advisor. Svas Biosana were advised at the contract stage by Attilio Ferrari and Andrea Pedeferri of Law Firm CFMP Studio Legale Associato.

***

IMI Fondi Chiusi SGR is the Intesa San Paolo Group’s asset management company that manages closed-end funds dedicated to qualifying traders. Specialising in the SME segment, it operates on three complementary activity lines - Private Equity, Venture Capital and Seed Capital - broken down into seven funds with Assets Under Management totalling 330 million euro. Atlante Private Equity is the private equity fund and was launched in 2010 by IMI Fondi Chiusi SGR for investments in SMEs, the segment that best represents the Italian business community. The Fund closed subscriptions in 2001 with a total amount of 200 million euro.

Set up in 1970, the Svas Biosana Group today has over 200 employees and a turnover of 47 million euro. The Group operates in the medical devices sector through Svas Biosana S.r.l., and manufactures and sells infusion solutions through Industria Farmaceutica Galenica Senese S.r.l.

 


For further information:
Intesa Sanpaolo
Media Relations - Corporate and Investment Banking
Tel.: +39.02.87963851/2489
stampa@intesasanpaolo.com

{"toolbar":[{"label":"Refresh","url":"","key":"update-page"},{"label":"Print","url":"","key":"print-page"}]}